Legalization of medical cannabis for treatment in Europe

medical cannabis for treatment

Founded in 2014, GreenLight Pharmaceuticals Ltd is an Irish-based biopharma firm focused on the development of safe & effective plant-based medicines. GreenLight has specialized in clinical development & phytocannabinoid research. The firm is based in Dublin but has recently established a United Kingdom-based subsidiary and intends to expand its world of medical cannabis in Europe.

Medical cannabis refers to a vast range of products which contain active compounds and cannabidiol either manufactured chemically, secluded from the plant, or raw plant preparations.

In the past ten years Italy, Switzerland, France, Germany, and Spain have implemented medical cannabis access programs for particular indications. Last year the United Kingdom and Ireland also gave permission of medical use, but the prescribing process is still promising, restricting access and uptake.

Medical Cannabis is used for the treatment of Multiple Sclerosis, Chronic Pain & Epilepsy.

Standardized cannabis plant extracts of cannabidiol and THC delivered in similar quantities were the first CBMP to be authorized in the United Kingdom for the treatment of neuropathic pain & MS-related muscle spasm when there is an insufficient response to other treatments.

MS patients who received nabiximols together with existing treatment report less muscle spasticity than those receiving a placebo.

Chronic pain inclusive of musculoskeletal and neuropathic pain is the primary reason why patients seek medical cannabis in the United States. A 2018 Cochrane review of 14 trials by Mucke & his colleagues, revealed that a modest yet significant increase in the proportion of patients who achieved a 30% reduction in pain; 39% of cannabinoid treated versus 33% who had a placebo.

A 2018 systematic review by Stockings & his colleagues, summarizing RCTs of intractable epilepsy, revealed that adding cannabidiol to traditional anti-epileptic drugs considerably brings reduction to seizure frequency. GreenLight intends to conduct dose-finding trials for minimizing interactions with co-medications & adverse reactions.